Perspective Therapeutics (NYSE:CATX) Raised to Strong-Buy at Cantor Fitzgerald

Perspective Therapeutics (NYSE:CATX) was upgraded by Cantor Fitzgerald to a “strong-buy” rating in a research report issued on Tuesday,Zacks.com reports.

Other research analysts also recently issued research reports about the stock. Wedbush reaffirmed an “outperform” rating and issued a $11.00 target price on shares of Perspective Therapeutics in a report on Friday, January 24th. Bank of America downgraded shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $24.00 to $5.00 in a report on Monday, November 25th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $16.00 target price on shares of Perspective Therapeutics in a report on Tuesday, January 14th. Finally, Oppenheimer dropped their target price on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a report on Friday, November 22nd. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Perspective Therapeutics presently has a consensus rating of “Buy” and an average price target of $15.14.

Perspective Therapeutics Price Performance

Shares of CATX stock opened at $2.53 on Tuesday. Perspective Therapeutics has a 1 year low of $2.32 and a 1 year high of $19.05. The firm has a fifty day moving average price of $3.23 and a 200-day moving average price of $7.87.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Perspective Therapeutics by 19.6% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 70,150 shares of the company’s stock valued at $224,000 after purchasing an additional 11,472 shares during the last quarter. Velan Capital Investment Management LP bought a new position in shares of Perspective Therapeutics during the 4th quarter valued at about $1,595,000. Squarepoint Ops LLC bought a new position in shares of Perspective Therapeutics during the 4th quarter valued at about $626,000. Wexford Capital LP purchased a new stake in shares of Perspective Therapeutics during the 4th quarter valued at about $64,000. Finally, Two Sigma Advisers LP purchased a new stake in shares of Perspective Therapeutics during the 4th quarter valued at about $484,000. Institutional investors own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.